How many insider trades does FilingIQ track for LRMR?

FilingIQ tracks 50 Form 4 insider transactions for LRMR (Larimar Therapeutics, Inc.), covering filings from Jun 30, 2020 onwards. 1 of those are dated within the last 90 days.

Are LRMR insiders net buyers or net sellers?

Across the full Form 4 history for LRMR, 31 transactions (62%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LRMR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is LRMR in?

Larimar Therapeutics, Inc. (LRMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $446.78M.

LRMR insider trading

NasdaqGM Healthcare

Larimar Therapeutics, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

62% / 0%

Market cap

$446.78M

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Company website: larimartx.com

LRMR insider activity at a glance

FilingIQ tracks 50 insider transactions for LRMR in filings since Jun 30, 2020. The most recent transaction is dated Sep 29, 2026.

Across the full history, 31 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LRMR insider trades is 62.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LRMR trades on FilingIQ Raw filings on SEC EDGAR

Latest LRMR Form 4 filings

Harlow John B. Jr. President and COO

A Oct 1, 2026

Hamilton Thomas Edward

Hamilton Thomas Edward

A May 20, 2026

Flynn James E

P Mar 2, 2026

Hamilton Thomas Edward

P Mar 2, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for LRMR?: FilingIQ tracks 50 Form 4 insider transactions for LRMR (Larimar Therapeutics, Inc.), covering filings from Jun 30, 2020 onwards. 1 of those are dated within the last 90 days.
Are LRMR insiders net buyers or net sellers?: Across the full Form 4 history for LRMR, 31 transactions (62%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LRMR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is LRMR in?: Larimar Therapeutics, Inc. (LRMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $446.78M.

Methodology & sources

Every LRMR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.